Stephanie Brown became President North America and a member of Santhera’s Executive Management team on December 1, 2021. She joined Santhera with an extensive background leading commercial businesses and global franchises in North America and Europe. Previously, she was Senior Vice President and Head of the Rare Diseases Franchise, North America at Ipsen Pharmaceuticals. In this role, she was responsible for establishing a new rare disease business unit to market and launch medicines to treat rare conditions. Prior to Ipsen, Stephanie was Vice President and US Head of Novartis’ Neuroscience Franchise with responsibility for commercial marketing, sales and operations of this important business and had oversight of market access, patient services and medical affairs. Earlier in her career, Stephanie held various leadership roles at Takeda Pharmaceuticals US, Biogen, Genentech and Merck.

She is a member of the board of ObsEva SA (NASDAQ: OBSV; SIX: OBSN).

Stephanie earned a B.S. in Chemistry with Biology from Mount Allison University, Canada, and an MBA from Heriot-Watt University, Scotland.